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No Effect of a Whey Growth Factor Extract during Resistance Training on 
Strength, Body Composition, or Hypertrophic Gene Expression in Resistance- 
Trained Young Men 
Michael J. Dale, Alison M. Coates, Peter R.C. Howe, Grant R. Tomkinson, Matthew T. Haren, Andrew 
Brown, Marissa Caldow, David Cameron-Smith, Jonathan D. Buckley 
ABSTRACT 
Growth factors can be isolated from bovine milk to form a whey growth factor extract (WGFE). This 
study examined whether WGFE promoted activation of the AKT/mTOR pathway enabling increased lean 
tissue mass and strength in resistance trained men. Forty six men with >6 months of resistance training 
(RT) experience performed 12 weeks of RT. Participants consumed 20 g/day of whey protein and were 
randomised to receive either 1.6 g WGFE/day (WGFE; n = 22) or 1.6 g cellulose/day (control, CONT; n = 
24). The primary outcome was leg press one-repetition maximum (LP1-RM) which was assessed at 
baseline, 6 and 12 weeks. At baseline and 12 weeks body composition was assessed by dual energy x-ray 
absorptiometry, and muscle protein synthesis and gene expression were assessed (vastus lateralis biopsy) 
in a sub-sample (WGFE n = 10, CONT n = 10) pre- and 3 hr post-training. RT increased LP1-RM 
(+34.9%) and lean tissue mass (+2.3%; p < 0.05) with no difference between treatments (p > 0.48, 
treatment x time). Post-exercise P70s6k phosphorylation increased acutely, FOXO3a phosphorylation was 
unaltered. There were no differences in kinase signalling or gene expression between treatments. 
Compared with CONT, WGFE did not result in greater increases in lean tissue mass or strength in 
experienced resistance trained men. 
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INTRODUCTION 
Resistance training can increase strength and skeletal muscle mass, but the adaptive responses can be 
enhanced through an increased protein intake, and in particular an increased intake of whey protein (Cribb 
et al., 2006; Miller et al., 2014). Whey protein is a rich source of amino acids including branched-chain 
amino acids (BCAA) that are critical for increasing muscle protein synthesis (Ha and Zemel, 2003) and 
also contains small amounts of growth factors which may contribute to increases in muscle size and 
strength (Walzem et al., 2002). Other dairy foods that are rich in growth factors have also been shown to 
improve muscular adaptations to resistance training, such as bovine colostrum. Bovine colostrum is the 
first milk produced by cows after calving and contains high concentrations of growth factors (Francis et 
al., 1988). Bovine colostrum has been shown to increase lean tissue mass (Antonio et al., 2001) and 
muscular power (Buckley et al., 2003) when consumed during resistance exercise training. However, the 
availability of colostrum is limited relative to that of normal cow’s milk. This has led to the development 
of chromatography technologies to extract growth factors from milk and/or whey (Francis et al., 1995) to 
produce growth factor-rich products to potentially increase muscular adaptations to exercise training. 
Whey Growth Factor Extract (WGFE) is a concentrated protein source consisting primarily of 
Lactoperoxidase (62%) and Lactoferrin (16%) proteins, but is also enriched in other growth factors such 
as insulin-like growth factors (Collier et al., 1991) that are naturally present in milk at low concentrations. 
A preliminary study using untrained volunteers indicated that WGFE supplementation (2 g/day) during 12 
weeks of resistance training resulted in ~35% greater increase in leg strength (Carey et al., 2006; 
Crittenden et al., 2009). However, whether WGFE enhances strength increases in individuals who are 
already resistance trained is unclear. 
 
Muscle hypertrophy in response to resistance training requires activation of the AKT/mTOR pathway 
(Philp et al., 2011), which can be activated by IGF-1 (Rommel et al., 2001). This pathway activates the 
ribosomal complex and initiates translation downstream of the kinase P70s6k, increasing the rate of new 
protein synthesis. Simultaneously intense exercise may stimulate the ubiquitin proteasome pathway and 
the induction of muscle-specific E3-ubiquitin ligases, atrogin-1 and muscle RING finger-1 (MuRF1) 
which promote muscle turnover (Rahbek et al., 2015; Stefanetti et al., 2014). This is achieved by the E3- 
ubiquitin ligases regulating transcription of the Forkhead Box (FOXO) proteins, including the FOXO3 
isoform (Okamoto et al., 2011). There is evidence that the ingestion of dairy protein can influence the 
mTOR pathway (Mitchell et al., 2015), possibly due to its IGF-1 content (Rommel et al., 2001), but not 
the FOXO pathway (Stefanetti et al., 2014). Studies are yet to address the actions of WGFE on these 
pathways. 
The aim of this study was to examine the effect of supplementation with WGFE on muscle strength, body 
composition and molecular pathways controlling skeletal muscle hypertrophy in men with a history of 
resistance exercise training. We hypothesised that WGFE would promote activation of the AKT/mTOR 
pathway and thus increase muscle anabolism enabling greater increases in lean tissue mass and strength. 
METHODS 
This study used a randomised, double-blind, placebo-controlled parallel design. All participants undertook 
a 12-week progressive resistance exercise training program and were allocated to concurrent daily 
consumption of 20 g of whey protein isolate together with 1.6 g of cellulose (CONT n = 24) or 1.6 g of 
WGFE (n = 22). A dose of 1.6 g/day, rather than the 2 g/day used in the preliminary study (Carey et al., 
2006; Crittenden et al., 2009), was chosen to improve the commercial viability of the product as a 
supplement by reducing cost per effective dose. Ten participants from each group underwent vastus 
lateralis muscle biopsies pre- and post-training at baseline and after the 12-week training program. To 
account for potential confounding effects of differences in baseline muscle strength participants were 
allocated to treatment via minimisation (Altman and Bland, 2005) based upon peak isometric knee 
extension torque data collected during a pre-intervention familiarisation session. Participants were further 
stratified on the basis of training experience and age. Assessments at baseline and after the 12-week 
training program were performed at the same time of day to control for circadian variation. A diagram of 
the study protocol is provided in Figure 1. This study was approved by the Human Research Ethics 
Committee of the University of South Australia and conformed to the standards set by the Declaration of 
Helsinki. All participants provided written informed consent prior to participating. 
Figure 1. Diagram of study protocol. WGFE – Whey growth factor extract. WPI – whey protein isolate. DXA – dual 
energy x-ray absorptiometry. RT – resistance training. KE – knee extensor. LP-1RM – leg press one repetition maximum. 
WFR – weighed food record. 
Participants 
Adult males aged 18-30 years who had been participating in regular (>2 sessions per week) resistance 
exercise training for at least six months immediately prior to the study were recruited via public 
advertisement. All participants reported being free from current or prior musculoskeletal injury which 
would prevent them from undertaking the training required for the study. Prospective participants were 
excluded if they were: (a) smokers or had recently (within the previous 6 months) quit smoking; (b) 
engaged in other athletic training that might confound the outcomes of the present study; (c) consumed 
prescription medication; (d) were allergic to/sensitive to/intolerant of dairy proteins or lactose; or (e) had 
recently (within the past 6 months) taken any form of supplement intended to increase physical 
performance or enhance recovery. All potential participants were administered the Sports Medicine 
Australia pre-exercise screening questionnaire (Sports Medicine Australia, 2005), with only those 
classified as low risk accepted into the study. 
 
Supplements 
All study supplements were commercially available products (Murray Goulbum Co-Operative Co Ltd, 
Melbourne, Australia). The protein and growth factor composition of the WGFE supplement is provided 
in Table 1. Both WGFE and CONT groups consumed 20 g of whey protein isolate powder daily, mixed 
with 250 mL of water. Additionally both groups consumed four capsules each morning. Those randomised 
to the WGFE group consumed capsules each containing 400 mg of whey growth factor extract (i.e. 1.6 g 
dose; Catalyst, Murray Goulbum, Parkville, Australia), whilst each CONT capsule contained 400 mg of 
cellulose (i.e. 1.6 g dose). The capsules were identical in appearance. Supplements were consumed 
immediately upon rising on non-training days and immediately after training on training days. Compliance 
with supplementation was determined by capsule counting. 
Table 1. Composition of whey growth factor extract. 
Compositional components Content 
Protein 
Total protein content (% w/w)* 97.5 
Lactoperoxidase (% w/w)* 41.2 
Lactoferrin (% w/w)* 23.8 
RNase 5 (% w/w) † 8 
IgG (% w/w)* 6.7 
IgA (% w/w) †† 6.1 
RNase 4 (% w/w) † 4 
Growth factors 
Transforming growth factor-β2 (ng/mg protein) †† 45.8 
Insulin-like growth factor I (ng/mg protein) †† 27.1 
Insulin-like growth factor II (ng/mg protein) †† 20 
Platelet derived growth factor (ng/mg protein) †† 4 
Betacellulin (ng/mg protein) †† .4 
Fibroblast growth factor 1 (ng/mg protein) †† .4 
* Analysis performed by *Dairy Technical Services Ltd, Melbourne, Australia 
†Murray Goulburn Co-operative Ltd, Melbourne, Australia 
††TGR Biosciences, Adelaide, Australia. 
 
Anthropometry and body composition measures 
At baseline height was measured using a stadiometer (SECA, Hamburg). Body mass was measured using 
digital scales (Tanita Ultimate Scale, Tokyo) at baseline and after 6 and 12 weeks and mid-thigh girth was 
measured using a tape (Lufkin, Apex Tool Group, Maryland) following International Society for the 
Advancement of Kinanthropometry (ISAK) protocols (Marfell-Jones et al., 2007). Body composition was 
assessed at Weeks 0 and 12 using dual-energy x-ray absorptiometry (DXA, Lunar Prodigy, General 
Electric, Madison, WI, USA, using enCORE 2003 software version 7.52.002), with whole body and 
regional (right thigh) non-bone lean and fat tissue mass determined. The thigh segment assessed in the 
regional analysis was defined as the area bordered distally by a line passing through the medial and lateral 
joint spaces of the knee, parallel to the tibial plateau and proximally by a line passing immediately distal to 
the most inferior point of the ischial tuberosity and immediately proximal to the superior border of the 
greater trochanter. Medial and lateral borders included all lower limb soft tissue falling between the 
proximal and distal boundaries. Test-retest reliability for data extraction was assessed on baseline DXA 
scans from all 46 subjects. Region of interest data were extracted from the same scan on separate days, 
and reliability of extraction was excellent for both lean tissue mass (ICC ± 95%CI: 1.000 ± 0.001) and fat 
tissue mass (ICC ± 95%CI: 1.000 ± 0.001). 
Strength measures 
Maximal isometric torque of the right knee extensors was assessed using an isokinetic dynamometer 
(Biodex System 4, Biodex Medical Systems Inc, Shirley, NY). Participants were positioned on the 
dynamometer with the knee joint flexed to 90° and the axis of rotation of the knee joint aligned with the 
axis of rotation of the lever arm of the dynamometer. The lever arm of the dynamometer was strapped to 
the participants’ ankle at 3 cm above the medial malleolus. Seat position data (seat pan depth, seat rail 
location, lever arm length) were recorded to enable replication of position for subsequent testing. Three 
sub-maximal warm-up efforts of 5 seconds duration were performed with a 1-minute rest between efforts. 
After a 2-minute rest, three maximal 5-second isometric efforts were performed with a 1-minute rest 
between. Test-retest reliability was assessed using data from two testing sessions separated by 1-2 weeks 
on all 46 subjects. Reliability for maximal isometric torque was excellent (ICC ± 95%CI: 0.92 ± 0.05). 
One-repetition maximum (1RM) testing was performed for incline leg press following American College 
of Sports Medicine (ACSM) guidelines (American College of Sports Medicine, 2006). 
Non-biopsy participants began training 2-3 days after baseline testing, to allow for recovery from the 1RM 
testing procedure. Participants undergoing biopsies began training on the day of their biopsy, which 
occurred 4-7 days after baseline testing. 
 
Resistance training intervention 
Participants were familiarised with the strength testing protocols and the resistance training program prior 
to commencement of testing. Each participant underwent a 2-hour familiarisation session to ensure correct 
technique for all exercises comprising the testing and training program. The resistance training program 
consisted of a whole-body, non-periodised, progressive program designed to improve strength and 
hypertrophy. Participants trained at the research facility gymnasium three times per week with 24-72 hours 
between training sessions. The following exercises were performed in order: bench press, smith machine 
hack squat, lat pulldown, incline leg press, weighted dip, preacher bench biceps curl, seated row, seated 
calf raise, and sit-ups. All exercises (except sit-ups) were performed using custom-made resistance 
equipment (Maxim, Adelaide, Australia). 
Three sets of 12 repetitions per exercise were attempted (except for the sit-ups where three sets of 20 
repetitions were attempted), with a 1-minute rest period between sets and a 2-minute rest period between 
exercises. Lifting was continued until concentric failure or the 12 or 20 repetition target was reached. The 
number of repetitions per set was recorded by each participant in a training diary, with participant- 
selected increases (typically 2.5 to 10.0 kg, dependent upon the exercise) occurring when the participant 
could successfully perform three sets of 12 repetitions at the target resistance. Progression for the 
unweighted sit-ups task occurred through increases in the numbers of repetitions, with a 2-repetition 
increase occurring when three sets of 20 repetitions could be successfully performed. The total volume of 
training per treatment group was quantified as the total number of exercises x number of sets x number of 
repetitions x resistance (kg), and was expressed per training session. All training sessions were supervised 
in order to ensure correct technique was used and compliance with the training program. 
Muscle biopsy 
A sub-population from each treatment group (WGFE and CONT, n=10 per group) underwent muscle 
biopsies at 1 hour pre- and 3 hours post-training at Weeks 0 and 12. Muscle tissue (~100 mg) from the 
right vastus lateralis muscle ~15 cm above the patella was harvested by a registered Medical Practitioner 
using the percutaneous biopsy technique (Bergstrom) modified to include suction under a 1% lignocaine 
local anaesthetic. Tissue was immediately visualised at x10 magnification, blotted free of blood and 
cleaned of any connective tissue, and then snap frozen in liquid nitrogen and stored at -80° C. Posttraining 
biopsy samples were collected through the same incision but with the biopsy needle angled inferiorly and 
medially to avoid the pre-training biopsy site, with different incisions at Week 0 and 12. 
Western blotting 
Tissue samples (10 mg) were homogenised in cell lysis buffer following the manufacturer’s instructions 
(Biorad, Hercules, CA) using a tissue disruptor for 20 seconds at a speed setting of 5.5 (FastPrep, Thermo-
Fisher Scientific, Australia). The homogenate was frozen at -80° C for 10 min then rotated at 4° C for 1 
hour. The lysate was centrifuged at 13000 rpm at 4° C for 10 minutes and the supernatant collected. 
Protein concentration was determined using the BCA protein assay kit, following the manufacturer’s 
instructions (Thermo-Fisher Scientific, Australia). Protein (50 pg) was separated by 8% SDS-PAGE. The 
proteins were transferred onto a nitrocellulose membrane and blocked in 5% bovine serum albumin (BSA) 
in Tris Buffered Saline with 0.1% Tween 20 (TBST) for 2 hours at room temperature. Primary antibodies, 
diluted in blocking buffer (1:1000) were applied and incubated overnight at 4° C; p-mTOR (Ser2448), 
mTOR, p-p70S6K (Thr389), p70S6K, p-Akt (Ser473), Akt, p- FOXO3a (Ser253), and FOXO3a (Cell 
Signalling Technology Inc., Danvers, MA). Membranes were washed six times for 5 minutes with TBST 
and incubated for 1 hour at room temperature with corresponding HRP-conjugated antibodies; rabbit 
(Merck Biosciences, Australia). Membranes were then washed six times for 5 minutes with TBST and 
proteins were detected by enhanced chemiluminescence (Western Lighting Chemiluminescence Reagent 
Plus, Perkin Elmer Lifesciences, Boston, MA). The density of the bands was quantified using a Kodak 
Image Station (Model: 440CF, Eastman Kodak Company, USA) and quantified by densitometry software 
(Kodak 1D 3.5). Membranes were stripped using Restore™ Western Blot Stripping Buffer (Thermo-
Fisher Scientific, Australia) for 30 minutes before being re-probed with the total antibody, to confirm that 
changes observed in phosphorylation were not due to changes in total protein levels. 
Reverse transcription polymerase chain reaction (RT-PCR) 
RNA was extracted from the vastus lateralis biopsies (5-7 mg) using the Totally RNA kit (Applied 
Biosystems, Foster City, CA). RNA quality and concentration were determined (Nanodrop 1000, Thermo-
Fisher Scientific, Australia). First-strand cDNA was generated using 0.5 pg of total RNA via the RNA-to-
cDNA kit (Applied Biosystems, Foster City, CA). RT-PCR was performed in triplicate using the ABI7500 
sequence detection system (Applied Biosystems, Foster City, CA), with reaction volumes of 14 pl, 
containing Power SYBR Green (Applied Biosystems, Foster City, CA), forward and reverse primers and 
cDNA template (1.25 ng/ul). Data were analysed using a comparative critical threshold (Ct) method where 
the amount of target was normalised to the amount of endogenous control, relative to control value given 
by 2-AACt (Applied Biosystems, Foster City, CA). The efficacy of Cyclophilin, 18S, TBP and GAPDH as 
endogenous controls was examined using the equation 2-ACt. GAPDH gene expression showed no change 
in response to exercise (data not shown) and was therefore used for normalisation of the target gene. 
Dietary intake 
Food intakes were recorded at baseline, Week 6 and Week 12 using 3-day weighed food records which 
included at least one weekend day. Energy intake, macro and micronutrient profiles were calculated using 
Foodworks® Nutritional software (Xyris Software, Pty Ltd, Highgate Hill, Queensland; Australia). 
Statistical analysis 
Data were only analysed for participants who completed the intervention. Data are presented throughout as 
means±standard deviation (SD) unless otherwise indicated. Student’s t-tests were used to compare group 
means at baseline. To determine the effects of the treatment, time of measurement and their interactions on 
the outcome measures, data were analysed using a Random Effects Model (REM). Parameters were 
established using restricted maximum likelihood (REML) rather than maximum likelihood (ML) due to 
the relatively small sample. Post-hoc testing was performed to localise the main effects, where relevant, 
using sequential Bonferroni corrected t-tests. The Pearson correlation was used to determine relationships 
between parameters. Due to the potential for baseline strength to influence the magnitude of increase in 
strength participants were stratified on the basis of baseline leg strength (isometric knee extension 
strength) and secondary analysis was undertaken to evaluate whether there were differences in strength 
gains in different tertiles of baseline strength. NCSS version 7.0 (NCSS, Kaysville, USA) or SPSS version 




A total of 93 prospective participants were screened for inclusion. Sixty eight participants were enrolled 
into the study and completed baseline testing, with 46 completing the study (Figure 2). These participants 
were highly compliant to the training (completing 92% of scheduled training sessions) and the supplement 
protocols (96% of supplement capsules consumed). At baseline the CONT and WGFE groups were well 
balanced by age, height, mass and training experience (Table 2). 
Figure 2. CONSORT diagram indicating participant flow through study. 
Table 2. Participant characteristics at baseline. Data are shown as mean (±standard deviation). 
 CONT group(n = 34) WGFE group(n = 33) 
Age, yr 21.8 (2.9) 21.9 (3.2) 
Height, m 1.8 (.1) 1.8 (.1) 
Mass, kg 75.0 (9.8) 76.4 (11.1) 
TR experience, months 20.6 (18.0) 28.6 (34.3) 
TR = Training, CONT = Control, WGFE = Whey Growth Factor Extract (WGFE) 
 
Leg strength and training load 
Data for leg strength and loads lifted during training are presented in Table 3. Both CONT and WGFE 
increased isometric knee extensor strength and leg press strength (LP1-RM; primary outcome) during the 
study period, but there was no difference between groups (p > 0.85, treatment x time). 
Table 3. Leg strength and training loads. Values are mean (±SD). 
 CONT group (n = 24) WGFE group (n = 22) 
Week 0 Week 6 Week 12 Week 0 Week 6 Week 12 
Incline leg press 1RM, kg 280(46) 354(65)* 373(65)*† 289(56) 364(48)* 389(52)*† 
Maximum Isometric knee-extensor Force, Nm 295(64) 306(63)* 314(67)*† 285(47) 297(45)* 301(51)*† 
Load lifted per training session, kg - 19421 (3386) 20064 (4457) - 19104 (3253) 19072 (4798) 
CONT = Control, WGFE = Whey Growth Factor Extract. 
*significantly different from Week 0 (p < 0.05) 
†significantly different from Week 6 (p < 0.05). 
 
Secondary analysis of incline leg press strength data showed that baseline strength was inversely 
correlated with the change in strength by Week 12 in the WGFE group (r = -0.49; P=0.03) but not in the 
CONT group (r = -0.05; p = 0.80). Accordingly, for participants in the lowest tertile of leg press strength 
at baseline there was a significantly greater increase in leg press strength in those who consumed WGFE 
compared with CONT (p = 0.002; treatment effect). 
Anthropometry and body composition 
Data for anthropometric and body composition measures are reported in Table 4. Body mass increased 
during the study period (p < 0.05 for time), with no difference between treatments (p = 0.98, treatment x 
time). The body mass increases were driven by increases in non-bone lean tissue mass which also 
increased (p < 0.001 for time), with no difference between treatments (p = 0.85, treatment x time). 
Table 4. Anthropometric and body composition measures. Values are mean (±SD). 
 CONT group (n = 24) WGFE group (n = 22) 
Week 0 Week 6 Week 12 Week 0 Week 6 Week 12 
Body Mass, kg 75.0 (9.8 75.9 (9.5) 76.1 (9.3)* 76.4 (11.1) 77.1 (10.3) 77.4 (10.8)* 
Whole Body non-bone Lean Tissue Mass, kg 58.7 (5.7) - 60.0 (5.8)* 60.0 (6.9) - 61.3 (7.0)* 
Whole Body Fat Mass, kg 12.2 (4.6) - 12.2 (4.7) 12.5 (6.8) - 12.3 (6.0) 
Thigh non-bone Lean Tissue Mass, kg 6.3 (.9) - 6.5 (.9)* 6.6 (.9) - 6.8 (1.0)* 
Thigh Fat Mass, kg 2.0 (.7) - 2.0 (.8) 2.0 (.1) - 2.1 (.1) 
Thigh Girth, cm 52.2 (3.8) 53.2 (3.7)* 53.4 (3.5)* 52.9 (4.5) 53.8 (4.0)* 53.8 (4.0)* 
CONT = Control, WGFE = Whey Growth Factor Extract. 
*significantly different from Week 0 (p < 0.05) 
†significantly different from week 6 (p < 0.05). 
 
Regional analysis of the thigh revealed small but significant increases in non-bone lean tissue mass (p < 
0.05 for time), with no difference between treatments (p = 0.37, treatment x time). Participants in the 
lowest tertile of leg press strength at baseline had significantly less non-bone lean tissue in their thighs 
compared with those in the upper tertiles (p < 0.05). However, the increases in non-bone lean tissue mass 
of the thigh during the training period for participants in this lower tertile did not differ between treatments 
(p = 0.85 treatment x time). Non-bone lean tissue mass in the thighs was strongly correlated with leg press 
strength at baseline (r = 0.55, p < 0.001), but changes in thigh non-bone lean tissue mass by Week 12 were 
not correlated with changes in leg press strength (r = 0.08, p = 0.63). Thigh girth increased during the 
study period (p < 0.001 for time), but there was no significant treatment x time interaction (p = 0.72). 
Protein levels and gene expression 
The ratios of phosphorylated to non-phosphorylated protein, and mRNA expression data, are presented in 
Table 5. 
Table 5. Protein phosphorylation and mRNA expression. Values are mean (±SD). 
 CONT group (n = 10) WGFE group (n = 10) 
Week 0 Week 12 Week 0 Week 12 
Pre-exercise Post-exercise Pre-exercise Post-exercise Pre-exercise Post-exercise Pre-exercise Post-exercise 
Phosphorylated to non-phosphorylated protein ratio 
AKT1 1.00 (.00) 2.23 (2.58) .91 (.61) 1.25 (1.00) 1.00 (.00) 1.62 (2.30) 1.89 (2.48) .84 (1.20) 
mTOR 1.00 (.00) 1.52 (.98) 1.14 (1.40) 2.61 (2.84) 1.00 (.00) 3.79 (4.99) 1.60 (1.56) 5.47 (4.75)*‡ 
p70s6k 1.00 (.00) 4.86 (5.13)* 1.46 (1.24) 3.64 (4.42) 1.00 (.00) 2.50 (2.09) .78 (.50) 4.95 (3.16) 
FOXO3a 1.00 (.00) 1.04 (1.03) 1.64 (1.89) 1.31 (1.20) 1.00 (.00) .94 (.38) .97 (.25) 1.16 (.81) 
mRNA expression 
IGF-1Ea mRNA 1.00 (.00) .77 (.56) .96 (.52) .78 (.31) 1.00 (.00) 1.21 (1.02) 1.40 (.49) .98 (.76) 
Atrogin-1 mRNA 1.00 (.00) .60 (.54) 1.07 (.51) .41 (.24) 1.00 (.00) .57 (.41) 1.58 (1.24)† .80 (.60)‡ 
MHC I mRNA 1.00 (.00) 1.14 (.56) 1.28 (1.06) 1.13 (.94) 1.00 (.00) 1.37 (.66) 1.50 (.94) .95 (.79) 
MHC IIa mRNA 1.00 (.00) 1.01 (.48) .87 (.48) .95 (.82) 1.00 (.00) 1.27 (.84) 1.48 (1.14) .86 (.35) 
MHC IIx mRNA 1.00 (.00) 1.16 (1.58) 1.10 (2.27) .48 (.39) 1.00 (.00) 1.00 (.67) 1.48 (1.76) .94 (.91) 
CONT = Control, WGFE = Whey Growth Factor Extract. 
*significantly different from Week 0 pre-exercise 
†significantly different from Week 0 pre-exercise. 
‡significantly different from Week 12 pre-exercise. 
 
The only differences in treatment effects on protein phosphorylation ratios were for mTOR and p70s6k. At 
Week 12 there was no difference in pre-exercise mTOR protein phosphorylation ratios between treatments 
(p = 0.51), but mTOR phosphorylation increased significantly post-exercise in the WGFE group (p < 0.01) 
but not CONT. In addition there was a large increase in p70s6k protein phosphorylation post-exercise at 
Week 0 in CONT (385.9%, p = 0.04), but no significant change in the WGFE group. 
In relation to effects on mRNA expression, in the WGFE group pre-exercise Atrogin-1 gene expression 
levels at Week 12 were significantly higher than at Week 0 (p < 0.05) and decreased significantly from 
pre- to post-exercise (-49.7%, p = 0.03). No such changes were evident in CONT. 
Dietary intake 
There were no differences in energy or macronutrient intake between groups at baseline (p > 0.17, Table 
6). Energy intake, protein intake and carbohydrate intakes decreased during the study period (p < 0.02), 
but with no difference between groups (p > 0.18 treatment x time). Fat intake did not change (p = 0.32). 
Table 6. Daily energy and macronutrient intakes. Values are mean (±SD). 
 CONT group (n = 24) WGFE group (n = 22) 
Week 0 Week 6 Week 12 Week 0 Week 6 Week 12 
Energy Intake, Kcal 2747(884) 2317(645) 9.3 (3.8) 2222(908) 2891(669) 2317(478) 
Protein Intake, g 133(45) 114(45) 105(55) 123(31) 127(30) 108(25) 
Fat Intake, g 109(50) 89(33) 97(64) 104(28) 112(34) 91(29) 
Carbohydrate Intake, g 279(99) 245(102) 219(80) 325(107) 313(89) 252(54) 
 
DISCUSSION 
The main finding of the present study was that supplementation with 1.6 g/day of WGFE during 12 weeks 
of resistance training in resistance-trained young men did not enhance increases in muscle strength or lean 
tissue mass. Although there was a large increase (i.e. 34%) in the primary outcome of incline leg press 
strength across the 12-week training program, strength improvements were similar in both treatment 
groups and thus independent of WGFE supplementation. 
The magnitude of increase (% increase from baseline) in incline leg press strength in the present study was 
only ~25-30% of the increase reported in the previous study in untrained men (Carey et al., 2006; 
Crittenden et al., 2009) which found that WGFE promoted greater increases in strength. It is well 
established that the magnitude of training adaptations are contingent upon training status, and that the 
gains in muscular strength that can be achieved decline with increased training experience (Peterson et al., 
2005), so it was not unexpected that the magnitude of strength increase in the present study would be 
smaller. However, in the present study there was no evidence of WGFE enhancing strength increases as 
had been reported previously in untrained men (Carey et al., 2006; Crittenden et al., 2009). This may have 
been due to the lower dose of 1.6 g/day used in the present study compared with the 2 g/day dose used in 
the previous study. Interestingly though, there was an inverse relationship between leg press strength at 
baseline and the strength increase in the WGFE treatment group that was not apparent in CONT, 
indicating that individuals taking WGFE who were less strong at baseline achieved larger gains than 
stronger individuals. Secondary analysis of the leg press data comparing effects of WGFE and control 
across tertiles of baseline leg press strength revealed that in the lowest tertile, participants who consumed 
WGFE achieved greater strength increases than those who consumed CONT. This finding is consistent 
with that of our earlier study (Crittenden et al., 2009) which reported greater increases in strength with 
WGFE in untrained novices in so far as individuals with lower levels of strength, who may be less well- 
trained and therefore more similar to novices, appear to benefit from WGFE supplementation while better-
trained individuals do not. Thus, WGFE supplementation appears to provide no additional benefit for 
experienced lifters who are already reasonably strong, but may provide benefits for less strong or novice 
lifters. 
Anthropometric and body composition changes in this study were small and did not differ between 
treatment groups. Despite the small magnitude of whole body mass changes in this study, the changes 
detected were primarily the result of increases in non-bone lean tissue. These non-bone lean tissue mass 
increases, in combination with the small increases observed in thigh girth, suggest that skeletal muscle 
hypertrophy was induced by the training undertaken, but there was no additional benefit of WGFE 
supplementation. The increases in body weight and non-bone lean tissue mass were achieved despite 
decreases in energy, protein and carbohydrate intakes during the study in both groups. The reduction in 
dietary intake might have been a result of the daily supplementation with 20 g of whey protein in both 
treatment groups as whey protein increases satiety and suppresses food intake compared with 
carbohydrates or other proteins (Luhovyy et al., 2007). 
 
Control of skeletal muscle hypertrophy and atrophy resides, in part, within the mTOR and the ubiquitin- 
proteasome pathways respectively (Glass, 2005). Increased phosphorylation and activation of the effector 
kinase, p70s6k, which interacts with the ribosomal protein S6, was measured within 3 hours of the 
resistance exercise bouts. This is consistent with previous studies demonstrating rapid activation with 
resistance exercise, particularly with the ingestion of supplemental whey protein (Burke et al., 2012; 
Farnfield et al., 2009). However, WGFE supplementation did not significantly alter the response, either at 
the first exercise session or at the end of the intervention period. Upstream of p70s6k, the phosphorylation 
of the Ser2448 residue of mTOR tended to increase with exercise only with WGFE supplementation. It is 
not clear what impact this phosphorylation site has on the kinase activity of mTOR, with the suggestion 
that this is a feedback inhibitory phosphorylation site. There was no activation of FOXO3a 
phosphorylation, consistent with previous studies demonstrating either suppressed or unchanged 
phosphorylation in the first few hours after resistance exercise (Stefanetti et al., 2014). Correspondingly 
there was a tendency for Atrogin-1 mRNA to be suppressed post-exercise, with no significant treatment 
effect. Collectively, these signalling and molecular data, plus analysis of the expression of MHC genes, 
fail to demonstrate a significant action of WGFE on either hypertrophic or atrogenic cellular pathways. 
CONCLUSION 
Supplementation with 1.6 g/day of WGFE during resistance exercise training might provide an advantage 
for increasing strength in untrained individuals (i.e. novices) or individuals who are less well-adapted to 
training, but not for individuals who are already well adapted to strength training. 
ACKNOWLEDGEMENTS 
We thank Professor Garry Scroop (MBBS, MD, PhD) for collecting the muscle biopsy samples for this 
study. All authors contributed to study design. MJD collected the data. MJD, JDB, MKC and DC-S 
analysed the data. All authors contributed to data interpretation and manuscript preparation. The study was 
funded by Murray Goulburn Co-Operative Co Ltd. A Brown is an employee of Murray Goulburn Co-
operative Co Ltd. The other authors have no conflicts of interest. MT Haren was supported by a Post-
doctoral Training Fellowship (Public Health) from the National Health and Medical Research Council 
(NHMRC) of Australia (# 511345). The experiments described comply with the current laws of Australia, 
where the research was performed. 
REFERENCES 
Altman, D. and Bland, M. (2005) Treatment allocation by minimisation. British Medical Journal 330, 
843. 
American College of Sports Medicine. (2006) ACSM's Guidelines for Exercise Testing and Prescription. 
7th edition. Baltimore: Lippincott Williams and Wilkins. 
Antonio, J., Sanders, M. and Van Gammeren, D. (2001) The effects of bovine colostrum supplementation 
on body composition and exercise performance in active men and women. Nutrition 17, 243-247. 
Buckley, J., Brinkworth, G. and Abbott, M. (2003) Effect of bovine colostrum on anaerobic exercise 
performance and plasma insulin-like growth factor I. Journal of Sports Sciences 21, 577- 588. 
Burke, L.M., Hawley, J.A., Ross, M.L., Moore, D.R., Phillips, S.M., Slater, G.R., Stellingwerff, T., 
Tipton, K.D., Garnham, A.P. and Coffey, V.G. (2012) Preexercise aminoacidemia and muscle 
protein synthesis after resistance exercise. Medicine and Science in Sports and Exercise 44, 1968-
77. 
Carey, K., Larsen, A., Rowney, M. and Cameron-Smith, D. (2006). Application of Whey Proteins to 
Enhance the Molecular Adaptations and Strength Gains Following Resistance Exercise Training. 
In: Fourth International Whey Conference, Chicago USA. 279-291. 
Collier, R.J., Miller, M.A., Hilderbeandt, J.R., Torkelson, A.R., White, T.C., Madsen, K.S., Vicini, J.L., 
Eppard, P.J. and Lanza, G.M. (1991) Factors affecting insulin like growth factor 1 
concentration in bovine milk. Journal of Dairy Science 74, 2905-2911. 
Cribb, P.J., Williams, A.D., Carey, M.F. and Hayes, A. (2006) The effect of whey isolate and resistance 
training on strength, body composition, and plasma glutamine. International Journal of Sport 
Nutrition and Exercise Metabolism 16, 494-509. 
Crittenden, R., Buckley, J., Cameron-Smith, D., Brown, A., Thomas, K., Davey, S. and Hobman, P. 
(2009) Functional dairy protein supplements for elite athletes. Australian Journal of Dairy 
Technology 64, 133-137. 
Farnfield, M.M., Carey, K.A., Gran, P., Trenerry, M.K. and CameronSmith, D. (2009) Whey protein 
ingestion activates mTORdependent signalling after resistance exercise in young men: a 
double- blinded randomized controlled trial. Nutrients 1, 263- 275. 
Francis, G.L., Regester, G.O., Webb, H.A. and Ballard, F.J. (1995) Extraction from cheese whey by 
cation-exchange chromatography of factors that stimulate the growth of mammalian cells. 
Journal of Dairy Science 78, 1209-1218. 
Francis, G.L., Upton, F.M., Ballard, F.J., McNeill, K.A. and Wallace, J.C. (1988) Insulin-like growth 
factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a 
potent truncated form. Biochemical Journal 251, 95- 103. 
Glass, D. (2005) Skeletal muscle hypertrophy and atrophy signalling pathways. International Journal of 
Biochemistry and Cell Biology 37, 1974-1984. 
Ha, E. and Zemel, M.B. (2003) Functional properties of whey, whey components, and essential amino 
acids: mechanisms underlying health benefits for active people (review). Journal of Nutritional 
Biochemistry 14, 251-258. 
Luhovyy, B.L., Akhavan, T. and Anderson, G.H. (2007) Whey proteins in the regulation of food intake 
and satiety. Journal of the American College of Nutrition 26, 704S-12S. 
Marfell-Jones, M., Olds, T., Stewart, A. and Carter, L. (2007) International standards for anthropometric 
assessment. Potchefstroom: International Society for the Advancement of Kinathroopometry. 
Miller, P.E., Alexander, D.D. and Perez, V. (2014) Effects of Whey Protein and Resistance Exercise on 
Body Composition: A Meta-Analysis of Randomized Controlled Trials. Journal of the American 
Colege ofl Nutrition 33, 163-175. 
Mitchell, C.J., Della Gatta, P.A., Petersen, A.C., Cameron-Smith, D. and Markworth, J.F. (2015) Soy 
protein ingestion results in less prolonged p70S6 kinase phosphorylation compared to whey 
protein after resistance exercise in older men. Journal of the International Society of Sports 
Nutrition 12, 6. 
Okamoto, T., Torii, S. and Machida, S. (2011) Differential gene expression of muscle-specific ubiquitin 
ligase MAFbx/Atrogin1 and MuRF1 in response to immobilization-induced atrophy of slow- 
twitch and fast-twitch muscles. Journal of Physiological Sciences 61, 537-546. 
Peterson, M.D., Rhea, M.R. and Alvar, B.A. (2005) Applications of the dose-response for muscular 
strength development: a review of meta-analytic efficacy and reliability for designing training 
prescription. Journal of Strength and Conditioning Research 19, 950-958. 
Philp, A., Hamilton, D.L. and Baar, K. (2011) Signals mediating skeletal muscle remodeling by resistance 
exercise: PI3-kinase independent activation of mTORC1. Journal of Applied Physiology 110, 
561-568. 
Rahbek, S.K., Farup, J., de Paoli, F. and Vissing, K. (2015) No differential effects of divergent isocaloric 
supplements on signaling for muscle protein turnover during recovery from muscle-damaging 
eccentric exercise. Amino Acids 47, 767-778. 
Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt, T.N., Yancopoulos, G.D. and 
Glass, D.J. (2001) Mediation of IGF-1-induced skeletal myotube hypertrophy by 
PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biology 3, 1009-1013. 
Sports Medicine Australia. (2005). Sports Medicine Australia (SMA) pre-exercise screening system 2005. 
Australian Government Department of Health and Ageing. 
Stefanetti, R.J., Lamon, S., Rahbek, S.K., Farup, J., Zacharewicz, E., Wallace, M.A., Vendelbo, M.H., 
Russell, A.P. and Vissing, K. (2014) Influence of divergent exercise contraction mode and whey 
protein supplementation on atrogin-1, MuRF1, and FOXO1/3A in human skeletal muscle. 
Journal of Applied Physiology 116, 1491-502. 
Walzem, R.L., Dillard, C.J. and German, J.B. (2002) Whey components: millennia of evolution create 
functionalities for mammalian nutrition: what we know and what we may be overlooking. Crit 
Rev Food Sci Nutr 42, 353-375. 
